Literature DB >> 16448325

Fungal infections in bone marrow transplant recipients.

Tuhina Raman1, Paul E Marik.   

Abstract

Invasive fungal infections (IFIs) can cause significant morbidity and mortality in patients after haematopoietic stem cell transplantation. The two most notorious pathogenic fungal species in this group of patients are Candida and Aspergillus. Risk factors for IFIs include: prolonged neutropaenia; fungal overgrowth and conditioning regiment-related mucositis; graft versus host disease; and steroid therapy. Clinical manifestations can be protean, and radiological changes are frequently nonspecific. Diagnostic methods include culture- and nonculture-based techniques. Some experts recommend IFI prophylaxis in the high-risk groups, such as patients with severe graft versus host disease who require prolonged immunosuppressive therapy or patients with a previous history of aspergillosis. Treatment options include therapy with azoles, including the newer agent voriconazole, amphotericin and caspofungin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16448325     DOI: 10.1517/14656566.7.3.307

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  [Immunodeficiency and immunocompromised patients. Opportunistic infection of the lungs].

Authors:  F Länger; H H Kreipe
Journal:  Pathologe       Date:  2011-09       Impact factor: 1.011

2.  Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis.

Authors:  Heather R Conti; Fang Shen; Namrata Nayyar; Eileen Stocum; Jianing N Sun; Matthew J Lindemann; Allen W Ho; Justine Hoda Hai; Jeffrey J Yu; Ji Won Jung; Scott G Filler; Patricia Masso-Welch; Mira Edgerton; Sarah L Gaffen
Journal:  J Exp Med       Date:  2009-02-09       Impact factor: 14.307

Review 3.  Microbial threat lists: obstacles in the quest for biosecurity?

Authors:  Arturo Casadevall; David A Relman
Journal:  Nat Rev Microbiol       Date:  2010-01-11       Impact factor: 60.633

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.